Ronan Rocle

Marketing Manager – Innovative Technologies

The 3rd annual Ligase Targeting Drug Development conference, which will take place next week on April 11^th-13^th in Boston this year, gathers the community of companies and academic laboratories involved in the discovery and development of PROTACs (proteolysis-targeting chimeras), a new therapeutic modality for therapeutic targets previously considered undruggable.

As a major CDMO, Seqens supports PROTACs development through its small molecule API development and manufacturing capabilities, including for potent molecules, and bioavailability improvement services.